克立硼罗治疗特应性皮炎:瘙痒与生活质量关联分析
BACKGROUND: Pruritus is a leading cause of reduced health-related quality of life (QoL) in atopic dermatitis (AD). Crisaborole ointment is a non-steroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate AD.…
要点
- 瘙痒严重度SPS与DLQI、CDLQI、DFI均呈线性关系。
- SPS 0分对应无负面影响,3分对应极大影响生活质量。
- 改善瘙痒可能直接提升患者及照护者生活质量。
核心结论
- SPS与DLQI、CDLQI和DFI的关系证实瘙痒与特应性皮炎患者及照护者生活质量显著相关。
研究设计与样本
- 汇总两项相同III期研究(NCT02118766、NCT02118792)数据,患者≥2岁随机2:1接受克立硼罗或赋形剂每日两次共28天。
主要发现
- DLQI分析n=294,CDLQI分析n=1200,DFI分析n=1293,SPS与各QoL指标线性关系成立。
- SPS评分0、1、2、3分别对应DLQI无负面影响、小影响、中等影响、极大影响。
- SPS与CDLQI和DFI的关系模式与DLQI相似。
关键数值与推荐
- SPS为4点量表:0为无瘙痒,3为烦人的瘙痒/搔抓干扰睡眠。
- QoL测量:DLQI用于≥16岁患者,CDLQI用于2-15岁患者,DFI用于2-17岁患者的照护者。
临床怎么用
- 临床可依据SPS评分快速评估瘙痒对生活质量的影响程度。
- 治疗中应重视瘙痒控制以改善患者及照护者的生活质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pruritus is a leading cause of reduced health-related quality of life (QoL) in atopic dermatitis (AD). Crisaborole ointment is a non-steroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate AD. In identical Phase 3 studies (NCT02118766, NCT02118792), crisaborole reduced disease and pruritus severity versus vehicle. OBJECTIVE: Quantify the relationship between pruritus and QoL using data from these studies. METHODS: Patients aged ≥2 years were randomly assigned 2 : 1 to receive crisaborole:vehicle twice daily for 28 days. QoL was measured at baseline and day 29 using the Dermatology Life Quality Index (DLQI; patients aged ≥16 years), the Children's Dermatology Life Quality Index (CDLQI; patients aged 2-15 years) and the Dermatitis Family Impact (DFI; caregivers of patients aged 2-17 years). Pruritus was measured using the Severity of Pruritus Scale (SPS), a 4-point scale from 0 ('no itching') to 3 ('bothersome itching/scratching that disturbs sleep'), and captured morning and evening via electronic diary. Data from crisaborole and vehicle arms were pooled for this analysis. A repeated-measures longitudinal model was used to estimate relationships between pruritus (SPS) and QoL (DLQI, CDLQI and DFI in separate analyses). RESULTS: One thousand five hundred and twenty two patients received crisaborole or vehicle. A linearity assumption for the relationship between SPS and DLQI (n = 294), CDLQI (n = 1200), and DFI (n = 1293) was appropriate. For DLQI, SPS score of 0 was associated with 'no negative effect on patient QoL'; SPS score of 1 was associated with 'small effect on patient QoL'; SPS score of 2 was associated with 'moderate effect on patient QoL'; and SPS score of 3 was associated with 'very large effect on patient QoL'. The pattern of relationships between SPS and CDLQI and DFI was similar. CONCLUSIONS: The relationships between SPS and DLQI, CDLQI and DFI substantiate the significant link between pruritus and patient/caregiver QoL in AD.
引用
- Ständer S, Yosipovitch G, Bushmakin AG, et al. Examining the association between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole. J Eur Acad Dermatol Venereol. 2019. PMID: 31132182. doi:10.1111/jdv.15712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。